A good business is not always a good buy. It depends on the price. AlphaGen's fair value is its estimate of what a share should be worth once the market has priced in the next 12 months. Comparing it with today's price tells you how much room there may be, or whether the price has already run past it.
Fair value is part of the Core plan. Free and Starter members get one complete Core valuation preview each week.

Four cases, not one number
Nobody knows exactly how the next year will go, so AlphaGen values each company in four cases. They are four versions of the same 12 months:
- Bear: a realistic bad year. Things go wrong, but not a disaster.
- Conservative: between bear and base.
- Base: the most likely outcome. Not a cautious midpoint, and not a hope.
- Bull: a realistic good year.
The Base case is the one AlphaGen leads with. It is marked Preferred on the company page.
Room to fair value
The room to fair value (also called upside) is the gap between today's price and the base-case fair value:
- A positive figure means the price is below AlphaGen's estimate. A +25% means the fair value is a quarter above today's price.
- A negative figure means the price is above the estimate.
It is the Value arm of the AlphaGen radar, and the Screener can filter on it.
How the fair value is built
Each company is valued one at a time, from its own filings and AlphaGen's market data. The research is done by AlphaGen's valuation desk, an AI analyst that works to fixed rules, while every calculation and check is done by AlphaGen's own code:
- Peer multiples: the company is valued with up to three methods (lenses) such as P/E, dividend yield, price to book and EV/EBITDA, using what similar companies trade at today, with the company itself left out.
- Parts added on top: other businesses the company owns, assets, cash, liabilities, projects and claims are valued separately and added or subtracted.
- Market conditions: interest rates, yields, inflation and input prices from a monthly market sheet feed the cases.
- No circular reasoning: the company's own share price, its own multiples and analysts' targets are deliberately not used, so the fair value is an independent view, not an echo of the market.
- Checks: the base case is cross-checked a second, different way, and the result is tested against the company's own record. A valuation that fails its checks is not published, and the previous one stays.
Each valuation has a confidence (high, medium or low) and is dated. A company is valued again after its next result.
Reading the Value chapter on a company page
- One bar per case, bear to bull, with today's price as a line across them. At a glance: which cases the price has already passed.
- The analysts' bar: the median target of external analysts and their range, where there is one. It is shown beside AlphaGen's view, not used in it.
- The full fair-value report folds open underneath: what the fair value says, what drives the value, the key risk, what is changing (catalysts marked In force, Announced or Not confirmed, each with what to watch), and for each case why the value is what it is, its key assumptions, its methods and weights, and what would confirm or invalidate it. It ends with the uncertainties to monitor and the sources.
Where else you see fair value
- The Value arm of the radar, on every card and company page
- The Screener ideas Strong, under fair value and Dividends, under fair value
- Your Portfolio's At fair value view: what your holdings would be worth at each case (see Portfolio Analysis)
- Your Watchlist's Business against fair value
- Alerts when a stock you follow reaches its fair value or closes far below it
How to use fair value well
- Read it with the scores and the trend, not on its own. A share far below fair value with a weak business and a falling price may be cheap for a reason.
- Look at the spread between cases. A narrow range means the company's next year is fairly predictable; a wide one means a lot depends on how things turn out.
- Check the key risk and what would invalidate the case before relying on the base figure.
- Remember it is an estimate, not a promise. It is AlphaGen's view of the next 12 months, and it changes as the company reports.